Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against a Mixture of Dermatophagoides Pteronyssinus and Dermatophagoides Farinae Allergen Extract

Trial Profile

Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against a Mixture of Dermatophagoides Pteronyssinus and Dermatophagoides Farinae Allergen Extract

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MM 09 (Primary) ; MM 09 (Primary)
  • Indications Hypersensitivity; Rhinitis; Rhinoconjunctivitis
  • Focus First in man; Therapeutic Use
  • Sponsors Inmunotek
  • Most Recent Events

    • 01 May 2022 According to an Inmunotek media release, Dr. Antonio Nieto is the principal investigator for this trial.
    • 16 Mar 2020 Primary endpoint (Concentration required to elicit a positive response after nasal provocation test (NPT)) has been met.
    • 16 Mar 2020 Results presented at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top